Business Wire

CD-CAPITAL

30.11.2022 11:05:38 CET | Business Wire | Press release

Share
CD Capital’s Carmel Daniele Successfully Nominated in 2022’s Edition of “100 Global Inspirational Women in Mining” (WIM100)

CD Capital is thrilled to announce Carmel Daniele’s successful nomination in 2022’s edition of “100 Global Inspirational Women in Mining” (WIM100), a biennial publication that celebrates the “above & beyond” contributions of women to the mining industry, across all roles, seniority and jurisdictions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005553/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carmel Daniele nominated in 2022's WIM100 (Photo: Business Wire)

CD Capital is proud that Ms Daniele has received this recognition for her pioneering work within the mining private equity sector. Ms Daniele, CD Capital’s Founder and Chief Investment Officer commented,

“I feel both honoured and humbled to have been nominated for this prestigious award to stand alongside many other pioneering women in our field. By working together, we make a powerful force in creating positive change for the future and inspiring other women to join our sector that is key to the greening of our planet for generations to come”.

Ms Daniele is a leader in her field, having established CD Capital in 2006, being one of the first in London to set up a dedicated fund focused on private mining assets and winning a prestigious mining finance industry award in 2008. She has since launched two further natural resource funds and has raised c.$1bn in capital from leading institutional investors. CD Capital’s global portfolio invests in the development of projects that will supply critical minerals for the green transition, as well as the key ingredients used in fertilisers to ensure food security for the world. Projects are primarily in jurisdictions that can rely on their own abundance of green energy, such as Latin America, Canada, Australia and Europe.

Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders. Ms Daniele also actively sponsors women studying Geology at Imperial College through its internship and mentoring programme.

The 100 Global Inspirational Women in Mining 2022 publication includes more on WIM100 on page 3 and features Ms Daniele on page 47. In 2022, WIM 100 received 915 nominations for 491 women in mining from 61 countries.

These 100 inspirational women have been chosen using the following selection criteria:

1. She is a trailblazer: A WIM100 woman is a pioneer. She is an innovator. She makes positive and impactful changes so the industry can operate in a more sustainable, inclusive and safer way.

2. She advocates and empowers: A WIM100 woman offers proactive advocacy to those working in the mining industry and beyond. She empowers her colleagues to ensure everyone feels heard, welcomed and respected.

3. She perseveres in the face of adversity: A WIM100 woman is resilient and determined. She has the courage to speak up, challenge the status quo and break barriers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005553/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye